General Information of Drug (ID: DM7OTQS)

Drug Name
JNJ-10311795 Drug Info
Synonyms
JNJ-10311795; CHEMBL374027; 518062-14-1; SCHEMBL1260969; GTPL6563; BDBM50208224; Phosphonic acid, (2-(3-((methyl(1-(2-naphthalenylcarbonyl)-4-piperidinyl)amino)carbonyl)-2-naphthalenyl)-1-(1-naphthalenyl)-2-oxoethyl)-; Phosphonic acid, P-(2-(3-((methyl(1-(2-naphthalenylcarbonyl)-4-piperidinyl)amino)carbonyl)-2-naphthalenyl)-1-(1-naphthalenyl)-2-oxoethyl)-; [2-[3-[methyl-[1-(naphthalene-2-carbonyl)piperidin-4-yl]carbamoyl]naphthalen-2-yl]-1-naphthalen-1-yl-2-oxoethyl]phosphonic acid
Indication
Disease Entry ICD 11 Status REF
Chronic obstructive pulmonary disease CA22 Phase 2 [1]
Cross-matching ID
PubChem CID
10146470
CAS Number
CAS 518062-14-1
TTD Drug ID
DM7OTQS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Drug(s) Targeting Chymase (CYM)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SUN13834 DMPK34E Gram-positive bacterial infection 1B74-1G40 Phase 2 [3]
ASB17061 DMNVU28 Atopic dermatitis EA80 Phase 2 [4]
BAY 11-42524 DM8SNEM Left ventricular dysfunction BD11 Phase 2 [5]
BAY 1142524 DMHKTGX Myocardial infarction BA41-BA43 Phase 2 [6]
2-(N-Morpholino)-Ethanesulfonic Acid DMZVHSB Discovery agent N.A. Investigative [7]
Benzylsulfinic Acid DM7XK28 Discovery agent N.A. Investigative [8]
KM-01221 DMG594K Cardiovascular disease BA00-BE2Z Investigative [9]
Y-40613 DM412IV Discovery agent N.A. Investigative [10]
Rac-2q DMD5TPH Discovery agent N.A. Investigative [11]
Phenylalanylmethane DMZNFT2 Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cathepsin G (CTSG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Peptide analog 59 DMZAMNX N. A. N. A. Patented [12]
Peptide analog 61 DM45JMT N. A. N. A. Patented [12]
Peptide analog 55 DMVLP8H N. A. N. A. Patented [12]
Peptide analog 60 DMMSTNA N. A. N. A. Patented [12]
Peptide analog 70 DMN43Q5 N. A. N. A. Patented [12]
Peptide analog 56 DMBCFJU N. A. N. A. Patented [12]
Peptide analog 57 DM6IQWE N. A. N. A. Patented [12]
Peptide analog 58 DM7X62M N. A. N. A. Patented [12]
Peptide analog 62 DM28NK0 N. A. N. A. Patented [12]
Aloxistatin DMGW07M Neurological disorder 6B60 Discontinued in Phase 3 [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cathepsin G (CTSG) TTQAJF1 CATG_HUMAN Inhibitor [2]
Chymase (CYM) TT8VUE0 CMA1_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6563).
2 Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem. 2007 Apr 19;50(8):1727-30.
3 Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis.Eur J Pharmacol.2008 Dec 28;601(1-3):186-91.
4 Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013 Aug;68(8):974-82.
5 ClinicalTrials.gov (NCT02452515) A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction.
6 Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers. Clin Pharmacol Drug Dev. 2019 May;8(4):467-479.
7 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2340).
10 Therapeutic potential of a specific chymase inhibitor in atopic dermatitis. Jpn J Pharmacol. 2002 Nov;90(3):214-7.
11 Identification of 6-substituted 4-arylsulfonyl-1,4-diazepane-2,5-diones as a novel scaffold for human chymase inhibitors. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3431-4.
12 Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
13 Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing. J Biol Chem. 2007 Jul 20;282(29):20836-46.